Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes

被引:8
|
作者
Chen, Juan [1 ]
Pang, Aiming [1 ]
Zhao, Yuanqi [1 ]
Liu, Li [1 ]
Ma, Runzhi [1 ]
Wei, Jialin [1 ]
Chen, Xin [1 ]
He, Yi [1 ]
Yang, Donglin [1 ]
Zhang, Rongli [1 ]
Zhai, Weihua [1 ]
Ma, Qiaoling [1 ]
Jiang, Erlie [1 ]
Han, Mingzhe [1 ]
Zhou, Jiaxi [1 ]
Feng, Sizhou [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
关键词
Allogeneic hematopoietic stem cell transplantation; poor graft function; graft rejection; risk factors; treatment; VERSUS-HOST-DISEASE; SPLEEN;
D O I
10.1080/16078454.2022.2042064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Graft failure (GF) is an intractable complication of transplantation, which can severely affect the efficacy of the graft; however, the characteristics, incidence, and risk factors of primary GF have not been well described. This study aimed to analyze the risk factors and outcomes of primary GF to swiftly identify high-risk patients for GF. Methods We performed a case-control study with a case-control ratio of 1:4 with 869 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2015 and December 2019 at our center. Results Nineteen (2.19%) patients experienced primary poor graft function (PGF), while eleven (1.27%) patients developed primary graft rejection (GR). Univariate and multivariate logistic analyses identified two independent risk factors for primary PGF: splenomegaly [P = 0.030; odds ratio (OR), 3.486; 95% confidence interval (CI), 1.139 to 13.109], and donor type [non-matched sibling donor (non-MSD)] (P = 0.018; OR, 4.475; 95% CI, 1.289 to 15.537). However, only donor type (non-MSD) was statistically significant (P = 0.020; OR, 19.432; 95% CI, 1.595 to 236.691) for primary GR. The overall survival was significantly lower in the primary PGF (P = 0.001) and GR group (P = 0.000), respectively, compared to the control group. Conclusion GF can significantly affect the overall survival of patients who underwent allo-HSCT, despite its considerably low incidence. A human leukocyte antigen-matched sibling donor should be the first choice for patients undergoing allo-HSCT for the prevention of GF. Moreover, splenomegaly is an independent risk factor for PGF, and caution must be exercised while treating such patients.
引用
收藏
页码:293 / 299
页数:7
相关论文
共 50 条
  • [31] Prevalence, Risk Factors, and Outcomes of Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
    Bertelli, Luca
    Cazzato, Salvatore
    Belotti, Tamara
    Prete, Arcangelo
    Ricci, Giampaolo
    Pession, Andrea
    [J]. PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2017, 30 (02) : 113 - 115
  • [32] PREVALENCE, RISK FACTORS AND OUTCOMES OF BRONCHIOLITIS OBLITERANS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Bertelli, L.
    Martoni, A.
    Bardasi, G.
    Massaccesi, E.
    Zama, D.
    Morello, W.
    Cazzato, S.
    Masetti, R.
    Rondelli, R.
    Prete, A.
    Pession, A.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 : S258 - S258
  • [33] Acute Renal Failure Following Allogeneic Hematopoietic Cell Transplantation: Incidence, Outcome and Risk Factors
    Helal, Imed
    Byzun, Anies
    Rerolle, Jean Philipe
    Morelon, Emanuel
    Kreis, Henri
    France, Marie
    Bruneel-Mamzer, Marie France
    [J]. SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2011, 22 (03) : 437 - 443
  • [34] Risk factors for poor graft function in 231 patients receiving allogeneic hematopoietic stem cell transplantation
    Giglio, F.
    Petralia, I. T.
    Lorentino, F.
    Clerici, T. D.
    Greco, R.
    Lazzari, L.
    Xue, E.
    Mastaglio, S.
    Piemontese, S.
    Farina, F.
    Marktel, S.
    Assanelli, A. A.
    Corti, C.
    Lupo-Stanghellini, M. T.
    Marcatti, M.
    Bernardi, M.
    Peccatori, J.
    Ciceri, F.
    [J]. BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 341 - 341
  • [35] Graft failure after allogeneic hematopoietic cell transplantation
    Mattsson, Jonas
    Ringden, Olle
    Storb, Rainer
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (01) : 165 - 170
  • [36] BRONCHIOLITIS OBLITERANS SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PREVALENCE, RISK FACTORS, AND OUTCOMES
    Au, B. K. C.
    Au, M. A.
    Chien, J. W.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S157 - S157
  • [37] Incidence, risk factors, and clinical outcomes of cataracts following hematopoietic stem cell transplantation
    Najima, Yuho
    Kakihana, Kazuhiko
    Ohashi, Kazuteru
    Yamamoto, Narumichi
    Kobayashi, Takeshi
    Yamashita, Takuya
    Sakamaki, Hisashi
    Akiyama, Hideki
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (06) : 508 - 510
  • [38] Primary graft failure in allogeneic hematopoietic stem cell transplantation - single center experience 1989-2017
    Mota, Diana
    Pratas, Edgar
    Vaz, Carlos Pinho
    Leite, Luis
    Branca, Rosa
    Roncon, Susana
    Campilho, Fernando
    Campos, Antonio
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 : 514 - 515
  • [39] Mini-review - Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation
    Wolff, SN
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 (07) : 545 - 552
  • [40] Second allogeneic haematopoietic stem cell transplantation: a treatment for graft failure
    Remberger, M.
    Mattsson, J.
    Olsson, R.
    Ringden, O.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 : S292 - S292